Prot #KZR‑616‑202: A Phase 2b, Randomized, Controlled Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis

Project: Research project

Project Details

StatusActive
Effective start/end date1/26/24 → 1/26/27

Funding

  • PPD Investigator Services, LLC (Prot #KZR-616-202 AMD 1 // Prot #KZR-616-202 AMD 1)
  • Kezar Life Sciences, Inc. (Prot #KZR-616-202 AMD 1 // Prot #KZR-616-202 AMD 1)